Publications

PubMed       PDB

*: Corresponding Author, §: Equally Contributed

124. J. Lategahn, J. Hardick, T. Grabe, J. Niggenaber, K. Jeyakumar, M. Keul, H. L. Tumbrink, C. Becker, L. Hodson, T. Kirschner, P. Klövekorn, J. Ketzer, M. Baumann, S. Terheyden, A. Unger, J. Weisner, M. P. Müller, W. A. L. van Otterlo, S. Bauer, and D. Rauh*
Targeting Her2-insYVMA with Covalent Inhibitors—A Focused Compound Screening and Structure-Based Design Approach
J. Med. Chem., 2020, accepted.

123. L. Goebel*, M. P. Müller, R. S. Goody* and D. Rauh
KRasG12C inhibitors in clinical trials: a short historical perspective
RSC Med. Chem., 2020, 11, 760-770.

122. P. Roser^§, J. Weisner^§, J. Stehle, D. Rauh*, and M. Drescher*
Conformational selection vs. induced fit: insights into the binding mechanisms of p38α MAP Kinase inhibitors
Chem. Commun., 2020, accepted.

121. I. Landel^§, L. Quambusch^§, L. Depta^§, and D. Rauh*
Spotlight on AKT: Current Therapeutic Challenges
ACS Med. Chem. Lett., 2020, 11(3), 225-227.

120. L. Quambusch, I. Landel, L. Depta, J. Weisner, N. Uhlenbrock, M. P. Müller, F. Glanemann, K. Althoff, J. T. Siveke, and D. Rauh*
Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
Angew. Chem. Int. Ed., 2019, 131(52), 18999-19005.

119. J. Lategahn, M. Keul, P. Klövekorn, H. L. Tumbrink, J. Niggenaber, M. P. Müller, L. Hodson, M. Flaßhoff, J. Hardick, T. Grabe, J. Engel, C. Schultz-Fademrecht, M. Baumann, J. Ketzer, T. Mühlenberg, W. Hiller, G. Günther, A. Unger, H. Müller, A. Heimsoeth, C. Golz, B. Blank-Landeshammer, L. Kollipara, R. Zahedi, C. Strohmann, J. G. Hengstler, W. van Otterlo, S. Bauer, and D. Rauh*
Inhibition of Osimertinib-Resistant Epidermal Growth Factor Receptor EGFR-T790M/C797S
Chemical Science, 2019, 10, 10789-10801.

118. J. Niggenaber, J. Hardick, J. Lategahn*, D. Rauh*
Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases
J. Med. Chem., 2019, 63(1), 40-51.

117. P. Wolle, J. Engel, S. Smith, L. Goebel, E. Hennes, J. Lategahn*, and D. Rauh*
Characterization of Covalent Pyrazolopyrimidine–MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7)
J. Med. Chem., 2019, 62(11), 5541-5546.

116. J. Weisner^§, I. Landel^§, C. Reintjes^§, N. Uhlenbrock^§, M. Trajkovic-Arsic, N. Dienstbier, J. Hardick, S. Ladigan, M. Lindemann, S. Smith, L. Quambusch, R. Scheinpflug, L. Depta, R. Gontla, A. Unger, H. Müller, M. Baumann, C. Schultz-Fademrecht, G. Günther, A. Maghnouj, M. P. Müller, M. Pohl, C. Teschendorf, H. Wolters, R. Viebahn, A. Tannapfel, W. Uhl, J. G. Hengstler, S. A. Hahn*, J. T. Siveke* and D. Rauh*
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-mutant Pancreatic and Colorectal Cancer
Cancer Research, 2019, 79(9), 2367-2378, Epub 2019 Mar 11.

115. N. Uhlenbrock^§, S. Smith^§, J. Weisner, I. Landel, M. Lindemann, T. A. Le, J. Hardick, R. Gontla, R. Scheinpflug, P. Czodrowski, P. Janning, L. Depta, L. Quambusch, M. P. Müller, B. Engels and D. Rauh*
Structural and Chemical Insights into the Covalent-allosteric Inhibition of the Protein Kinase Akt
Chemical Science, 2019, 10(12), 3573-3585, eCollection 2019 Mar 28.

114. D. Bartolini^§, M. Bührmann^§, M. L. Barreca, G. Manfroni, V. Cecchetti, D. Rauh, & F. Galli
Co-crystal structure determination and cellular evaluation of 1,4-dihydropyrazolo[4,3-c] [1,2] benzothiazine 5,5-dioxide p38α MAPK inhibitors
Biochemical and Biophysical Research Communications, 2019, 511(3), 579-586, Epub 2019 Feb 27.

113. P. Wolle, J. Hardick, S. J.F. Cronin, J. Engel, M. Baumann, J. Lategahn, J. M. Penninger, and D. Rauh*
Targeting the MKK7–JNK (Mitogen-Activated Protein Kinase Kinase 7–c Jun N-Terminal Kinase) Pathway with Covalent Inhibitors
J. Med. Chem., 2019, 62(5), 2843-2848, Epub 2019 Feb 21.

112. D. N. do Amaral, J. Lategahn, H. H. Fokoue, E.M.B. da Silva, C. M. R. Sant'Anna, D. Rauh, E. J. Barreiro, S. Laufer*, L. M. Lima*
A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives
Sci. Rep., 2019, 9(1), 14.

111. J. Fassunke^§, F. Müller^§, M. Keul^§, S. Michels^§, M.A. Dammert^§, A. Schmitt^§, D. Plenker, J. Lategahn, C. Heydt, J. Brägelmann, H.L. Tumbrink, Y. Alber, S. Klein, A. Heimsoeth, I. Dahmen, R.N. Fischer, M. Scheffler, M.A. Ihle, V. Priesner, A.H. Scheel, S. Wagener, A. Kron, K. Frank, K. Garbert, T. Persigehl, M. Püslek, S. Haneder, B. Schaaf, E. Rodermann, W. Engel-Riedel, E. Felip, E.F. Smit, S. Merkelbach-Bruse, H.C. Reinhardt, S.M. Kast, J. Wolf*, D. Rauh*, R. Büttner*, M.L. Sos*
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Nature Communications, 2018, 9(1), 4655.

110. P. Roser^§, J. Weisner^§, J.R. Simard, D. Rauh*, M. Drescher*
Direct monitoring of the conformational equilibria of the activation loop in the mitogen-activated protein kinase p38α.
Chem Comm (Camb), 2018, 23;54(85), 12057-12060.

109. B. Wiedemann^§, J. Weisner^§, D. Rauh*
Chemical modulation of transcription factors.
Med. Chem. Comm., 2018, 11;9(8), 1249-1272.

108. T. Grabe, J. Lategahn, D. Rauh*
C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?
ACS Med. Chem. Lett., 2018, 23;9(8), 779-782.

107. P. Wolle, J. Weisner, M. Keul, I. Landel, J. Lategahn*, D. Rauh*
RASPELD to Perform High-End Screening in an Academic Environment toward the Development of Cancer Therapeutics.
Chem. Med. Chem., 2018, 8;13(19), 2065-2072.

106. M. Schmidt, A. Romanovska, Y. Wolf, T.D. Ngyuen, A. Krupp, H.L. Tumbrink, J. Lategahn, J. Volmer, D. Rauh, S. Luetz, C. Krumm, J.C. Tiller*
Insights into the Kinetics of the Resistance Formation of Bacteria against Ciprofloxacin Poly(2-methyl-2-oxazoline) Conjugates.
Bioconjug. Chem., 2018, 15;29(8), 2671-2678.

105. R. Tesch, C. Becker, M.P. Müller, M.E. Beck, L. Quambusch, M. Getlik, J. Lategahn, N. Uhlenbrock, F.N. Costa, M.D. Polêto, P.S.M. Pinheiro, D.A. Rodrigues, C.M.R.Sant’Anna, F.F. Ferreira, H. Verli, C.A.M. Fraga*, D. Rauh*
An Unusual Intramolecular Halogen Bond Guides Conformational Selection.
Angew. Chem. Int. Ed. Engl., 2018, 26;57(31), 9970-9975.

104. S. Müller*, S. Ackloo, C.H. Arrowsmith, M. Bauser, J.L. Baryza, J. Blagg, J. Böttcher, C. Bountra, P.J. Brown, M.E. Bunnage, A.J. Carter, D. Damerell, V. Dötsch, D.H. Drewry, A.M. Edwards, J. Edwards, J.M. Elkins, C. Fischer, S.V.Frye, A. Gollner, C.E. Grimshaw, A. Ijzerman, T. Hanke, I.V. Hartung, S. Hitchcock, T. Howe, T.V. Hughes, S. Laufer, V.M. Li, S. Liras, B.D. Marsden, H. Matsui, J. Mathias, R.C. O’Hagan, D.R. Owen, V. Pande, D. Rauh, S.H. Rosenberg, B.L. Roth, N.S. Schneider, C. Scholten, K. Singh Saikatendu, A. Simeonov, M. Takizawa, C. Tse, P.R. Thompson, D.K. Treiber, A.Y. Viana, C.I. Wells, T.M. Willson, W.J. Zuercher, S. Knapp, A. Mueller-Fahrnow*
Donated Chemical Probes for Open Science
Elife, 2018, 7, e34311.

103. P. Wolle, M.P. Müller, D. Rauh*
Augmented Reality in Scientific Publications-Taking the Visualization of 3D Structures to the Next Level.
ACS Chem. Biol., 2018, 16;13(3), 496-499.

102. M.P. Müller, D. Rauh*
Try Me: Promiscuous Inhibitors Still Allow for Selective Targeted Protein Degradation.
Cell. Chem. Biol., 2018, 18;25(1), 4-6.

101. J. Lategahn, M. Keul, D. Rauh*
Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.
Angew. Chem. Int. Ed. Engl., 2018, 23;57(9), 2307-2313.

100. H. Kaitsiotou, M. Keul, J. Hardick, T. Mühlenberg, J. Ketzer, C. Ehrt, J. Krüll, F. Medda, O. Koch, F. Giordanetto, S. Bauer*, Rauh D*
Inhibitors to overcome secondary mutations in the stem cell factor receptor KIT.
J. Med. Chem., 2017, 60(21). 8801-15.

99. J. Engel^§, S. Smith^§, J. Lategahn, H.L. Tumbrink, L. Goebel, C. Becker, E. Hennes, M. Keul, A. Unger, H. Müller, M. Baumann, C. Schultz-Fademrecht, G. Günther, J.G. Hengstler, D. Rauh*
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
J. Med. Chem., 2017, 60(18), 7725-44.

98. M. Bührmann, J. Hardick, J. Weisner, L. Quambusch, D. Rauh*
Covalent Lipid Pocket Ligands Targeting p38α MAPK Mutants.
Angew. Chem. Int. Ed. Engl., 2017, 56(43), 13232-36.

97. J. Brägelmann, M.A. Dammert, F. Dietlein, J.M. Heuckmann, A. Choidas, S. Böhm, A. Richters, D. Basu, V. Tischler, C. Lorenz, P- Habenberger, Z. Fang, S. Ortiz-Cuaran, F. Leenders, J. Eickhoff, U. Koch, M. Getlik, M. Termathe, M. Sallouh, Z. Greff, Z. Varga, H. Balke-Want, C.A. French, M. Peifer, H.C. Reinhardt, L. Örfi, G. Kéri, S. Ansén, L.C. Heukamp, R. Büttner, D. Rauh, B.M. Klebl, R.K. Thomas*, M.L. Sos*
Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.
Cell. Rep., 2017, 19(20), 2833-45.

96. M. Bührmann, B.M. Wiedemann, M.P. Müller, J. Hardick, M. Ecke, D. Rauh*
Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK.
PLoS ONE, 2017, 12(9), e0184627.

95. S. Tomassi^§, J. Lategahn^§, J. Engel, M. Keul, H.L. Tumbrink, J. Ketzer, T. Mühlenberg, M. Baumann, C. Schultz-Fademrecht, S. Bauer, D. Rauh*
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.
J. Med. Chem., 2017, 60(6), 2361-72.

94. S. Smith, M. Keul, J. Engel, D. Basu, S. Eppmann, D. Rauh*
Characterization of Covalent-Reversible EGFR Inhibitors.
ACS Omega, 2017, 2(4), 1563-1575.

93. L. Robke, L. Laraia, M.A. Carnero Corrales, G. Konstantinidis, M. Muroi, A. Richters, M. Winzker, T. Engbring, S. Tomassi, N. Watanabe, H. Osada, D. Rauh, H. Waldmann*, Y.W. Wu, J. Engel
Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34.
Angew. Chem. Int. Ed. Engl., 2017, 56(28), 8153-57.

92. J. Halekotte, L. Witt, C. Ianes, M. Krüger, M. Bührmann, D. Rauh, C. Pichlo, E. Brunstein, A. Luxenburger, U. Baumann, U. Knippschild, J. Bischof*, C. Peifer*
Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1δ and Their Structural Relation to p38α MAPK.
Molecules, 2017, 22(4), 522.

91. H.K. Wentsch^§, N.M. Walter^§, M. Bührmann^§, S. Mayer-Wrangowski, D. Rauh, G.J.R. Zaman, N. Willemsen-Seegers, R.C. Buijsman, M. Henning, D. Dauch, L. Zender, S. Laufer*
Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine.
Angew. Chem. Int. Ed. Engl., 2017, 56(19), 5363-67.
 

90. M. Günther^§, J. Lategahn^§, M. Juchum, E. Döring, M. Keul, J. Engel, H.L. Tumbrink, D. Rauh, S.A. Laufer*
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
J. Med. Chem., 2017, 60(13), 5613-37.

89. N.M. Walter^§, H.K. Wentsch^§, M. Bührmann^§, S.M. Bauer, E. Döring, S. Mayer-Wrangowski, A. Sievers-Engler, N. Willemsen-Seegers, G. Zaman, R. Buijsman, M. Lämmerhofer, D. Rauh, S.A. Laufer*
Design, Synthesis and Biological Evaluation of Novel Type I½ p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency and Prolonged Target Residence Time by Interfering with the R Spine.
J. Med. Chem., 2017, 60(19), 8027-54.

88. M. Radi, R. Schneider, A.L. Fallacara, L. Botta, E. Crespan, C. Tintori, G. Maga, M. Kissova, A. Calgani, A. Richters, F. Musumeci, D. Rauh, S. Schenone*
A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant.
Bioorganic & Med. Chem. Let., 2016, 26(15), 3436-40.

87. J. Engel, C. Becker, J. Lategahn, M. Keul, J. Ketzer, T. Mühlenberg, K. Kollipara, C. Schultz-Fademrecht, R. P. Zahedi, S. Bauer, D. Rauh*
Insights into the inhibition of drug-resistant EGFR.
Angew. Chem. Int. Ed. Engl., 2016, 55(36), 10909-12.

86. C. Becker, S. Öcal, H.D. Nguyen, T. Phan, M. Keul, J.R. Simard, D. Rauh*
Monitoring conformational changes in the receptor tyrosine kinase EGFR.
ChemBioChem, 2016, 17(11), 990-4.

85. J. Engel, J. Lategahn, D. Rauh*
Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer.
ACS Med. Chem. Lett., 2016, 7(1), 2-5.

84. D. Rauh
Special Issue Focused on Two Areas Pertinent to Chemical Biology: Post-Translational Modifications and New Frontiers on Kinases.
ACS Chem. Biol., 2015, 7(1), 2-5.

83. J. Schöttle, S. Chatterjee, C. Volz, M. Siobal, A. Florin, D. Rokitta, Y. Hinze, F. Dietlein, D. Plenker, K. König, K. Albus, J.M. Heuckmann, D. Rauh, T. Franz, B. Neumaier, U. Fuhr, L.C. Heukamp, R.T. Ullrich*
Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer.
Oncotarget, 2015, 6(36), 38458-68.

82. J. Engel, A. Richters, M. Getlik, S. Tomassi, M. Keul, M. Termathe, J. Lategahn, C. Becker, S. Mayer-Wrangowski, C. Grütter, N. Uhlenbrock, J. Krüll, N. Schaumann, S. Eppmann, P. Kibies, F. Hoffgaard, J. Heil, S. Menninger, S. Ortiz-Cuaran, J.M. Heuckmann, V. Tinnefeld, R.P. Zahedi, M.L. Sos, C. Schultz-Fademrecht, R.K. Thomas, S.M. Kast*, D. Rauh*
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
J. Med. Chem., 2015, 58(17), 6844-63.

81. J. Weisner, R. Gontla, L. van der Westhuizen, S. Oeck, J. Ketzer, P. Janning, A. Richters, T. Mühlenberg, Z. Fang, A. Taher, V. Jendrossek, S.C. Pelly, S. Bauer, W.A.L. van Otterlo, D. Rauh*
Covalent-Allosteric Kinase Inhibitors.
Angew. Chem. Int. Ed. Engl., 2015, 54(35), 10313-6.

80. S.C. Mayer-Wrangowski, D. Rauh*
Monitoring ligand induced conformational changes for the identification of estrogen receptor agonists and antagonists.
Angew. Chem. Int. Ed. Engl., 2015, 54(14), 4379-82.

79. P. Schröder, T. Förster, S. Kleine, C. Becker, A. Richters, S. Ziegler, D. Rauh, K. Kumar, H. Waldmann*
Neuritogenic Militarinone-Inspired 4-Hydroxypyridones Target the Stress Pathway Kinase MAP4K4.
Angew. Chem. Int. Ed. Engl., 2015, 54(42), 12398-403.

78. F. Dietlein, B. Kalb, M. Jokic, E.M. Noll, A. Strong, L. Tharun, L. Ozretić, H. Künstlinger, K. Kambartel, W.J. Randerath, C. Jüngst, A. Schmitt, A. Torgovnick, A. Richters, D. Rauh, F. Siedek, T. Persigehl, C. Mauch, J. Bartkova, A. Bradley, M.R. Sprick, A. Trumpp, R. Rad, D. Saur, J. Bartek, J. Wolf, R. Büttner, R.K. Thomas, H.C. Reinhardt*
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
Cell, 2015, 162(1), 146-59.

77. D. Basu, A. Richters, D. Rauh*
Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR.
Bioorg. Med. Chem., 2015, 23(12), 2767-80.

76. A. Richters, D. Basu, J. Engel, M.S. Ercanoglu, H. Balke-Want, R. Tesch, R.K. Thomas, D. Rauh*
Identification and Further Development of Potent TBK1 Inhibitors
ACS Chem. Biol., 2015, 10(1), 289-98.

75. Z. Fang, J.R. Simard, D. Plenker, H.D. Nguyen, T. Phan, P. Wolle, S. Baumeister, D. Rauh*
Discovery of Inter-Domain Stabilizers - A Novel Assay System for Allosteric Akt Inhibitors.
ACS Chem. Biol., 2015, 10(1), 279-88.

74. J.R. Simard*, D. Rauh*
FLiK: A Direct-Binding Assay for the Identification and Kinetic Characterization of Stabilizers of Inactive Kinase Conformations.
Methods Enzymol., 2014, 548, 147-71.

73. C. Tintori, A.L. Fallacara, M. Radi, C. Zamperini, E. Dreassi, E. Crespan, G. Maga, S. Schenone, F. Musumeci, C. Brullo, A. Richters, F. Gasparrini, A. Angelucci, C. Festuccia, S. Delle Monache, D. Rauh, M. Botta*
Combining X-ray Crystallography and Molecular Modeling toward the Optimization of Pyrazolo[3,4-d]pyrimidines as Potent c-Src Inhibitors Active in Vivo against Neuroblastoma.
J. Med. Chem., 2014, 58(1), 347-61.

72. A. Richters, H.D. Nguyen, T. Phan, J.R. Simard, C. Grütter, J. Engel, D. Rauh*
Identification of type II and III DDR2 inhibitors.
J. Med. Chem., 2014, 57(10), 4252-62.

71. A. Tziridis, D. Rauh, P. Neumann, P. Kolenko, A. Menzel, U. Bräuer, C. Ursel, P. Steinmetzer, J. Stürzebecher, A. Schweinitz, T. Steinmetzer, M.T. Stubbs*
Correlating structure and ligand affinity in drug discovery: a cautionary tale involving second shell residues.
Biol. Chem., 2014, 395(7-8), 891-903.

70. F. Malchers, F. Dietlein, J. Schöttle, X. Lu, L. Nogova, K. Albus, L. Fernandez-Cuesta, J. M. Heuckmann, O. Gautschi, J. Diebold, D. Plenker, M. Gardizi, M. Scheffler, M. Bos, D. Seidel, F. Leenders, A. Richters, M. Peifer, A. Florin, P.S. Mainkar, N. Karre, S. Chandrasekhar, J. George, S. Silling, D. Rauh, T. Zander, R. T. Ullrich, H.C. Reinhardt, F. Ringeisen, R. Büttner, L.C. Heukamp, J. Wolf, R.K. Thomas*
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in squamous-cell lung cancer.
Cancer Discovery, 2014, 4(2), 246-57.

69. D. Rauh
A special thematic compilation/special issue crossover with Biochemistry, Journal of Medicinal Chemistry, and ACS Medicinal Chemistry Letters focused on kinases.
ACS Chem. Biol., 2014, 9(3), 579-80.

68. B. Baur, K. Storch, K.E. Martz, M.I. Goettert, A. Richters, D. Rauh and S.A. Laufer*
Metabolically Stable Dibenzo[b,e]oxepin-11(6H)-ones as Highly Selective p38 MAP Kinase Inhibitors: Optimizing Anti-Cytokine Activity in Human Whole Blood.
J. Med. Chem., 2013, 56(21), 8561-78.

67. C. Grütter, S. Sreeramulu, G. Sessa, D. Rauh*
Structural characterization of the RLCK family member BSK8: A pseudokinase with an unprecedented architecture.
J. Mol. Biol., 2013, 425(22), 4455-67.

66. A. Richters, J. Ketzer, C. Grütter, M. Getlik, R. Schneider, J.M. Heuckmann, S. Heynck, M.L. Sos, A. Gupta, A. Unger, C. Schultz-Fademrecht, R.K. Thomas, S. Bauer*, D. Rauh*
Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design.
J. Med. Chem., 2013, 56(14), 5757-72.

65. R. Schneider, A. Gohla, J.R. Simard, D.B. Yadav, Z. Fang, W.A.L. van Otterlo, D. Rauh*
Overcoming compound fluorescence in the FLiK screening assay with red-shifted fluorophores.
J. Am. Chem. Soc., 2013, 135(22), 8400-8.

64. R. Schneider, C. Beumer, J.R. Simard, C. Grütter, D. Rauh*
Selective Detection of Allosteric Phosphatase Inhibitors.
J. Am. Chem. Soc., 2013, 135(18), 6838-4.

63. R. Urich, G. Wishart, M. Kiczun, A. Richters, N. Tidten-Luksch, D. Rauh, B. Sherborne, P.G. Wyatt* and R. Brenk*
De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments.
ACS Chem. Biology, 2013, 8(5), 1044-52.

62. S. Sreeramulu, Y. Mostizky, H. Nahum, L. Amram, E. Shani, C. Grütter, D. Rauh, N. Ori, G. Sessa*
BSKs are partially redundant positive regulators of brassinosteroid signaling in Arabidopsis.
Plant Journal, 2013, 74(6), 905-19.

61. A.P. Antonchick, S. López-Tosco, J. Parga, S. Sievers, M. Schürmann, H. Preut, S. Höing, H.R. Schöler, J. Sterneckert, D. Rauh, H. Waldmann*
Highly Enantioselective Catalytic Synthesis of Neurite Growth-Promoting Secoyohimbanes.
Chemistry & Biology, 2013, 20(4), 500-9.

60. Z. Fang, C. Grütter, D. Rauh*
Strategies for the Selective Regulation of Kinases with Allosteric Modulators - Exploiting Exclusive Structural Features.
ACS Chem. Biol., 2013, 8(1), 58-70.

59. D. Rauh
Chemical Biology – current and next challenges.
ACS Chem. Biol., 2013, 8(1), 1-2.

58. S. Chatterjee, L.C. Heukamp, M. Siobal, J. Schöttle, C. Wieczorek, M. Peifer, D. Frasca, M. Koker, K. König, L. Meder, D. Rauh, R. Büttner, J. Wolf, R.A. Brekken, B. Neumaier, G. Christofori, R.K. Thomas, R.T. Ullrich*
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.
J. Clin. Invest., 2013, 123(4), 1732-40.

57. S. Fischer, H.K. Wentsch, S.C. Mayer-Wrangowski, M. Zimmermann, S.M. Bauer, K. Storch, R. Nieß, S.C. Koeberle, C. Grütter, F.M. Böckler, D. Rauh and S.A. Laufer*
Dibenzosuberones as p38 MAP kinase inhibitors with low ATP competitiveness and outstanding whole blood activity.
J. Med. Chem., 2013, 56(1), 241-53.

56. B. Over, S. Wetzel, C. Grütter, Y. Nakai, S. Renner, D. Rauh, H. Waldmann*
Natural product derived fragments for fragment-based ligand discovery.
Nat. Chem., 2013, 5(1), 21-8.

55. M.L. Sos, F. Dietlein, M. Peifer, H. Balke-Want, C. Müller, M. Koker, A. Richters, S. Heynck, J. Schöttle, F. Malchers, J.M. Heuckmann, D. Seidel, L.e Fernandez-Cuesta, P. Eyers, A.P. Antonchick, V.V. Vintonyak, P.M. Schneider, T. Ninomiya, D. Rauh, L.C. Heukamp, R.K. Thomas*
A framework for identification of actionable cancer genome dependencies in small cell lung cancer.
Proc. Natl. Acad. Sci., 2012, 109(42), 17034-9.

54. K. Martz, A. Dorn, B. Baur, V. Schattel, M. Goettert, S. Mayer-Wrangowski, D. Rauh, S.A. Laufer*
Targeting the Hinge Glycine Flip and the Activation Loop: Novel Approach to Potent p38alpha Inhibitors.
J. Med. Chem., 2012, 55(17), 7862-74.

53. S.C. Koeberle, S. Fischer, D. Schollmeyer, V. Schattel, C. Grütter, D. Rauh, S.A. Laufer*
Design, Synthesis, and Biological Evaluation of Novel Disubstituted Dibenzosuberones as Highly Potent and Selective Inhibitors of p38 Mitogen Activated Protein Kinase.
J. Med. Chem., 2012, 55(12), 5868-77.

52. M. Peifer, L. Fernández-Cuesta, M.L. Sos, J. George, D. Seidel, L.H. Kasper, D. Plenker, F. Leenders, R. Sun, T. Zander, R. Menon, M. Koker, I. Dahmen, C. Müller, D. Di Cerbo, H.U. Schildhaus, J. Altmüller, I. Baessmann, C. Becker, B. de Wilde, J. Vandesompele, D. Böhm, S. Ansén, F. Gabler, I. Wilkening, S. Heynck, J.M. Heuckmann, X. Lu, S.L. Carter, K. Cibulskis, S. Banerji, G. Getz, K.S. Park, D. Rauh, C. Grütter, M. Fischer, L. Pasqualucci, G. Wright, Z. Wainer, P. Russell, I. Petersen I, Y. Chen, E. Stoelben, C. Ludwig, P. Schnabel, H. Hoffmann, T. Muley, M. Brockmann, W. Engel-Riedel, L.A. Muscarella, V.M. Fazio, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D.A. Heideman, P.J. Snijders, F. Cappuzzo, C. Ligorio, S. Damiani, J. Field, S. Solberg, O.T. Brustugun, M. Lund-Iversen, J. Sänger, J.H. Clement, A. Soltermann, H. Moch, W. Weder, B. Solomon, J.C. Soria, P. Validire, B. Besse, E. Brambilla, C. Brambilla, S. Lantuejoul, P. Lorimier, P.M. Schneider, M. Hallek, W. Pao, M. Meyerson, J. Sage, J. Shendure, R. Schneider, R. Büttner, J. Wolf, P. Nürnberg, S. Perner, L.C. Heukamp, P.K. Brindle, S. Haas, R.K. Thomas*
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.
Nat. Genet., 2012, 44(10), 1104-10.

51. J. Heuckmann, D. Rauh, R.K. Thomas*
Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer.
J. Clin. Oncol., 2012, 30(27), 3417-20.

50. R. Brenk*, D. Rauh*
Change or be changed: Reflections of the workshop 'Future in Medicinal Chemistry'.
Bioorg. Med. Chem., 2012, 15;20(12), 3695-7.

49. C. Grütter, J.R. Simard, S.C. Mayer-Wrangowski, P.H. Schreier, J. Pérez-Martín, A. Richters, M. Getlik, O. Gutbrod, C.A. Braun, M.E. Beck,D. Rauh*
Targeting GSK3 from Ustilago maydis: Type-II kinase inhibitors as potential antifungals.
ACS Chem. Biol., 2012, 20;7(7), 1257-67.

48. R. Schneider, C. Becker, J.R. Simard, M. Getlik, N. Bohlke, P. Janning, D. Rauh*
A direct binding assay for the detection of type IV allosteric inhibitors of Abl.
J. Am. Chem. Soc., 2012, 6;134(22), 9138-41.

47. M. Getlik, J.R. Simard, M. Termathe, C. Grütter, M. Rabiller, W.A.L. van Otterlo, D. Rauh*
Fluorophore labeled kinase detects that bind within the MAPK insert of p38α kinase.
PLoS ONE, 2012, 7(7), e39713.

46. A. Koch, H. Rode, A. Richters, D. Rauh*, S. Hauf*
A chemical genetic approach for covalent inhibition of analog-sensitive Aurora kinase in fission yeast.
ACS Chem. Biol., 2012, 7(4), 723-3.

45. M. Getlik, C. Grütter, J. R. Simard, H. D. Nguyen, A. Robubi, B. Aust, W. A. L. van Otterlo* and D. Rauh*
Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
Eur. J. Med., 2012, 481-15.

44. S.C. Köberle, J. Romir, S. Fischer, A. Köberle, V. Schattel, W. Albrecht, C. Grütter, O. Werz, D. Rauh, T. Stehle, S.A. Laufer*
Skepinone-L: a p38 mitogen activated protein kinase (MAPK) inhibitor with unsurpassed selectivity and outstanding in vivo efficacy.
Nat. Chem. Biol., 2011, 8(2), 141-43.

43. J.M. Heuckmann, M. Hölzel, M.L. Sos, S. Heynck, H. Balke-Want, M. Koker, M. Peifer, J. Weiss, C.M. Lovly, C. Grütter, D. Rauh, W. Pao, R.K. Thomas*
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
Clin. Cancer Res., 2011, 17(23), 7394-401.

42. S. Tückmantel, J.N. Greul, P. Janning, A. Brockmeyer, C. Grütter, J.R. Simard, O. Gutbrod, M.E. Beck, K. Tietjen, D. Rauh*, P.H. Schreier*
Identification of fungal Aurora kinase as a prominent target for N-substituted diaminopyrimidines.
ACS Chem. Bio., 2011, 6(9), 926-33.

41. V.V. Vintonyak, K. Warburg, B. Over, K. Hübel, D. Rauh, H. Waldmann*
Identification and further development of thiazolidinones spiro-fused to indolin-2-ones as potent and selective inhibitors of Mycobacterium tuberculosis Protein Tyrosine Phosphatase B.
Tetrahedron, 2011, 67(35), 6713-29.

40. P.S. Hammerman, M.S. Sos, A.H. Ramos, C. Xu, A. Dutt, W. Zhou, L.E. Brace, B.A. Woods, W. Lin, J. Zhang, X. Deng, S.M. Lim, S. Heynck, M. Peifer, J.R. Simard, M.S. Lawrence, R.C. Onofrio, H.B. Salvesen, D. Seidel, T. Zander, J.M. Heuckmann, A. Soltermann, H. Moch, M. Koker, F. Leenders, F. Gabler, S. Querings, S. Ansén, E. Brambilla, C. Brambilla, P. Lorimier, O.T. Brustugun, A. Helland, I. Petersen, J.H. Clement, H. Groen, W. Timens, H. Sietsma, E. Stoelben, J. Wolf, D.G. Beer, M.S. Tsao, M. Hanna, C. Hatton, M.J. Eck, P.A. Jänne, B.E. Johnson, W. Winckler, H. Greulich, A.J. Bass, J. Cho, D. Rauh, N.S. Gray, K.K. Wong, E.B. Haura, R.K. Thomas* and M. Meyerson*
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Cancer Discovery, 2011, 1(1), 78-89.

39. V.V. Vintonyak, H. Waldmann*, D. Rauh*
Using small molecules to target protein phosphatases.
Bioorg. Med. Chem., 2011, 19(7), 2145-55.

38. H. Rode, M.L. Sos, C. Grütter, S. Heynck, J.R. Simard, D. Rauh*
Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino) isoquinoline-4-carbonitriles as inhibitors of Myosine Light Chain Kinase and Epidermal Growth Factor Receptor.
Bioorg. Med. Chem., 2011, 19(1), 429-39.

37. S. Klüter, J. Simard, H. Rode, C. Grütter, M. Rabiller, W. van Otterlo, D. Rauh*
Characterization of irreversible kinase inhibitors by detecting fluorescent changes during covalent bond formation.
Chem. Bio. Chem., 2010, 11(18), 2557-6.

36. J. Weiss, M. Sos*, D. Seidel, M. Peifer, T. Zander, J. Heuckmann, R. Ullrich, R. Menon, S. Maier, A. Soltermann, H. Moch, P. Wagener, F. Fischer, S. Heynck, M. Koker, J. Schöttle, F. Leenders, F. Gabler, I. Dabow, S. Querings, L. Heukamp, H. Balke-Want, S. Ansén, D. Rauh, I. Baessmann, J. Altmüller, Z.Wainer, M. Conron, G. Wright, B. Solomon, E. Brambilla, C. Brambilla, P. Lorimier, S. Solberg, O. T. Brustgun, W. Engel-Riedel, C. Ludwig, I. Petersen, J. Sänger, J. Clement, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D. Heideman, F. Cappuzzo, C. Ligorio, S. Damiani, R. Beroukhim, W. Pao, B. Klebl, M. Baumann, R. Buettner, K. Ernestus, E. Stoelben, J. Wolf, P. Nürnberg, S. Perner, R. Thomas*
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer.
Sci. Transl. Med., 2010, 2(62), 62-9.

35. A. Robubi, H. Waldmann, D. Rauh*
RAF kinase inhibitors in cancer treatment: like a bull in a china shop?
ChemBioChem, 2010, 11(12), 1645-8.

34. V.V. Vintonyak, K. Warburg, H. Kruse, S. Grimme, K. Hübel, D. Rauh and H. Waldmann*
Identification of Spiro-fused Indolin-2-one-thiazolidinones as Potent and Selective Inhibitors of Mycobacterium tuberculosis Protein Tyrosine Phosphatase B.
Angew. Chem. Int. Ed. Engl., 2010, 49(34), 5902-5.

33. A.P. Antonchick, C. Gerding-Reimers, M. Catarinella, S. Ziegler, D. Rauh and H. Waldmann*
Highly Enantioselective Synthesis and Cellular Evaluation of Natural Product-Inspired Spirooxindoles.
Nature Chemistry, 2010, 2(9), 735-40.

32. F.J. Dekker, O. Rocks, N. Vartak, S. Menninger, C. Hedberg, R. Balamurugan, S. Wetzel, S. Renner, M. Gerauer, B. Schölermann, M. Rusch, J.W. Kramer, D. Rauh, G.W. Coates, L. Brunsveld, P.I. Bastiaens*, H. Waldmann*
Small-molecule inhibition of APT1 affects Ras localization and signaling.
Nat. Chem. Biol., 2010, 6(6), 449-56.

31. S. Wetzel, W. Wilk, S. Chammaa, B. Sperl, A. Roth, A. Yektaoglu, S. Renner, T. Berg, C. Arenz, A. Giannis, T.I. Oprea, D. Rauh, M. Kaiser, H. Waldmann*
A Scaffold-Tree-Merging Strategy for Prospective Bioactivity Annotation of gamma-Pyrones.
Angew. Chem. Int. Ed. Engl., 2010, 49(21), 3666-70.

30. V. Pawar, M. Sos, H. Rode, M. Rabiller, S. Heynck, W. van Otterlo, R. Thomas, D. Rauh*
Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of EGFR.
J. Med. Chem., 2010, 53(7), 2892-901.

29. M. Rabiller, M. Getlik, S. Klüter, S. Tückmantel, A. Richters, J.R. Simard, D. Rauh*
Proteus in the World of Proteins: Conformational Changes in Protein Kinases.
Archiv der Pharmazie (Weinheim), 2010, 343(4), 193-206.

28. J.R. Simard, M. Getlik, C. Grütter, R. Schneider, S. Wulfert, D. Rauh*
Fluorophore-labeling of the glycine-rich loop as a method of identifying inhibitors which bind to active and inactive kinase conformations.
J. Am. Chem. Soc., 2010, 132(12), 4152-60.

27. M. Peifer, J. Weiss, M.L. Sos, M. Koker, S. Heynck, C. Netzer, S. Fischer, H. Rode, D. Rauh, J. Rahnenführer and R.K. Thomas*
Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling.
PLoS ONE, 2010, 5(1), e8919.

26. M.L. Sos, H. Rode, S. Heynck, M. Peifer, F. Fischer, S. Klüter, V. Pawar, C. Reuter, J. Heuckmann, J. Weiss, L. Ruddigkeit, M. Rabiller, M. Koker, J. Simard, M. Getlik, R.K. Thomas* and D. Rauh*
Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation.
Cancer Research, 2010, 70(3), 868-74.

25. S. Klüter, C. Grütter, M. Rabiller, V. Pawar, M. Getlik, J.R. Simard, D. Rauh*
Structure-based development of a displacement assay for the detection of stabilizers of inactive kinase conformations.
J. Med. Chem., 2010, 53(1), 357-67.

24. J.R. Simard, C. Grütter, V. Pawar, B. Aust, A. Wolf, M. Rabiller, S. Wulfert, A. Robubi, S. Klüter, C. Ottmann, D. Rauh*
High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38α.
J. Am. Chem. Soc., 2009, 131(51), 18478-88.

23. M.L. Sos, S. Fischer, R. Ullrich, M. Peifer, J. Heuckmann, M. Koker, S. Heynck, I. Stückrath, J. Weiss, F. Fischer, A. Goel, L. Regales, K. Politi, S. Perera, M. Getlik, L. Heukamp, S. Ansen, T. Zander, R. Beroukhim, H. Kashkar, K. Shokat, W. Sellers, D. Rauh, C. Orr, K. Hoeflich, L. Friedman, K. Wong, W. Pao, R. Thomas*
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.
Proc. Natl. Acad. Sci., 2009, 10618351-6.

22. J.R. Simard, M. Getlik, C. Grütter, V. Pawar, D. Rauh*
Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
J. Am. Chem. Soc., 2009, 131(37), 13286-96.

21. M. Getlik, C. Grütter, J. Simard, S. Klüter, M. Rabiller, H.B. Rode, A. Robubi, D. Rauh*
Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc.
J. Med. Chem., 2009, 52(13), 3915-26.

20. J.R. Simard, S. Klüter, C. Grütter, M. Rabiller, H.B. Rode, D. Rauh*
A new screening assay for allosteric inhibitors of cSrc.
Nat. Chem. Biol., 2009, 5(6), 394-6.

19. M.L. Sos, K. Michel, T. Zander, J. Weiss, P. Frommolt, M. Peifer, D. Li, R. Ullrich, M. Koker, F. Fischer, T. Shimamura, D. Rauh, C. Mermel, S. Fischer, I. Stückrath, S. Heynck, R. Beroukhim, W. Lin, W. Winckler, K. Shah, T. LaFramboise, W.F. Moriarty, M. Hanna, L. Tolosi, J. Rahnenführer, R. Verhaak, D. Chiang, G. Getz, M. Hellmich, J. Wolf, L. Girard, M. Peyton, B.A. Weir, T.-H. Chen, H. Greulich, J. Barretina, G.I. Shapiro, L.A. Garraway, A.F. Gazdar, J.D. Minna, M. Meyerson*, K.-K. Wong* and R.K. Thomas*
Predicting drug activity in non-small cell lung cancer based on genetic lesions.
J. Clin. Invest., 2009, 19(6), 1727-40.

18. J.R. Simard, D. Rauh*
Chemical and Structural Biology to Direct the Repurposing of Sulindac.
ChemMedChem, 2009, 41793-5.

17. V.V. Vintonyak, A.P. Antonchick, D. Rauh*, H. Waldmann*
The Therapeutic Potential of Phosphatase Inhibitors.
Curr. Opin. Chem. Biol., 2009, 13(3), 272-83.

16. S. Renner, W. van Otterlo, M. Dominguez Seoane, S. Möcklinghoff, B. Hofmann, S. Wetzel, A. Schuffenhauer, P. Ertl, T. Oprea, D. Steinhilber, L. Brunsveld, D. Rauh, H. Waldmann*
Bioactivity-Guided Mapping of and Navigation in Chemical Space.
Nat. Chem. Biol., 2009, 5(8), 585-92.

15. S. Wetzel, K. Klein, S. Renner, D. Rauh, T. Oprea, P. Mutzel, H. Waldmann*
Interactive Exploration of Chemical Space with Scaffold Hunter.
Nat. Chem. Biol., 2009, 5(8), 581-3.

14. A. Michalczyk, S. Klüter, H.B. Rode, J.R. Simard, C. Grütter, M. Rabiller, D. Rauh*
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
Bioorg. Med. Chem., 2008, 16(7), 3482-8.

13. R. Bateman, D. Rauh, B. Tavshanjian, and K.M. Shokat*
Human carbonyl reductase 1 is an S-nitrosogluathione reductase.
J. Biol. Chem., 2008, 283(51), 35756-62.

12. J.G. Kopycki, D. Rauh (co-first author), A.A. Chumanevich, P. Neumann, T. Vogt, and M.T. Stubbs*
Biochemical and structural analysis of substrate promiscuity in plant Mg2+-dependent O-methyltransferases.
J. Mol. Biol., 2008, 378(1), 154-64.

11. G. Triola, S. Wetzel, B. Ellinger, M. Koch, K. Hübel, D. Rauh, and H. Waldmann*
 ATP competitive inhibitors of d-alanine-d-alanine ligase based on protein kinase inhibitor scaffolds.
Bioorg. Med. Chem., 2009, 17(3), 1079-87.

10. D. Rauh* and H. Waldmann
Linking chemistry and biology for the study of protein function.
Angew. Chem. Int. Ed. Engl., 2007, 46(6), 826-9.

09. J.A. Blair, D. Rauh, C. Kung, C.H. Yun, Q.W. Fan, H. Rode, C. Zhang, M.J. Eck, W.A. Weiss, and K.M. Shokat*
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.
Nat. Chem. Biol., 2007, 3(4), 229-38.

08. R. Bateman, D. Rauh, and K.M. Shokat*
Glutathione traps formaldehyde by formation of a bicyclo[4.4.1]undecane adduct.
Org. Biomol. Chem., 2007, 5(20), 3363-70.

07. M.D. Simon, M.E. Feldman, D. Rauh, A.E. Maris, D.E. Wemmer, and K.M. Shokat*
Structure and properties of a re-engineered homeodomain protein-DNA interface.
ACS Chem. Biol., 2006, 1(12), 755-60.

06. M. Tanaka, R. Bateman, D. Rauh, E. Vaisberg, S. Ramachandani, C. Zhang, K.C. Hansen, A.L. Burlingame, J.K. Trautman, K.M. Shokat*, and C.L. Adams
An unbiased cell morphology-based screen for new, biologically active small molecules.
PLoS Biol., 2005, 3(5), e128.

05. D. Rauh, G. Klebe, and M.T. Stubbs*
Understanding protein-ligand interactions: the price of protein flexibility.
J. Mol. Biol., 2004, 335(5), 1325-41.

04. D. Rauh, G. Klebe, J. Stürzebecher, and M.T. Stubbs*
ZZ made EZ: influence of inhibitor configuration on enzyme selectivity.
J. Mol. Biol., 2003, 330(4), 761-70.

03. G. Radau*, J. Gebel, and D. Rauh
New cyanopeptide-derived low molecular weight thrombin inhibitors.
Arch. Pharm. (Weinheim), 2003, 336(8), 372-80.

02. D. Rauh, S. Reyda, G. Klebe, and M.T. Stubbs*
Trypsin mutants for structure-based drug design: expression, refolding and crystallisation.
Biol. Chem., 2002, 383(7-8), 1309-14.

01. G. Radau* and D. Rauh
Synthesis of a cyanopeptide-analogue with trypsin activating properties.
Bioorg. Med. Chem. Lett., 2000, 10(8), 779-81.